Skip to main content

Carina Masferrer Ferragutcasas

I am a phD student in the Biochemistry, Molecular Biology and Biomedicine program from the Universitat Autònoma de Barcelona. Since 2020 I have been developing my thesis in the Biomedical Research in Gynaecology group at the Vall d'Hebron Institute of Research (VHIR) under the supervision of Dr. Eva Colás. My research aims, on the one hand, to analyse, understand, and work on the molecular profile of patients with endometriosis. On the other hand, it is focused in exploring and improving new treatment strategies for endometrial cancer patients.

Institutions of which they are part

Postdoctoral researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Carina Masferrer Ferragutcasas

Institutions of which they are part

Postdoctoral researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

I am a phD student in the Biochemistry, Molecular Biology and Biomedicine program from the Universitat Autònoma de Barcelona. Since 2020 I have been developing my thesis in the Biomedical Research in Gynaecology group at the Vall d'Hebron Institute of Research (VHIR) under the supervision of Dr. Eva Colás. My research aims, on the one hand, to analyse, understand, and work on the molecular profile of patients with endometriosis. On the other hand, it is focused in exploring and improving new treatment strategies for endometrial cancer patients.

After studying my bachelor's degree in Biomedical Sciences at Universitat de Barcelona, I pursued the master's programme in Translational Biomedical Research at the Vall d'Hebron Institute of Research (VHIR), aiming to direct my professional career to the clinical field. Due to my interest in gynaecology, I carried out its curricular internship in the Biomedical Research in Gynaecology group, developing the project “Study of Phototrexate as a possible therapeutic agent for endometrial cancer”.

The sponsorship of the "Mocador Solidari" initiative, promoted by Vall d'Hebron with the collaboration of Natura and Judit Mascó as its ambassador, allowed me to join the group as a phD student under the supervision of Dr. Eva Colás. Within this project I am currently working to develop new therapeutic strategies for improving the treatment of endometrial cancer. This cancer is the most common gynaecologic malignancy, accounting for 6% of diagnosed cancers in women. More specifically, we are studying the efficacy of the combination of immunotherapy with the ABTL0812 molecule, which has previously demonstrated good results in this type of cancer. This could specially improve the therapeutic options of patients with aggressive subtypes of endometrial cancer.

Simultaneously, I also collaborate with the clinical team of the hospital's Gynaecology Service to analyse, understand, and work on the molecular profile of patients with endometriosis. We aim to progress and individualize their clinical management, regarding both the diagnostic process and therapeutic options, to improve the quality of life of those patients.

Projects

Cytomark - Desarrollo de un test diagnóstico personalizado y no invasivo de cáncer de endometrio en el fluido cervical

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Angel García Jiménez, Carina Masferrer Ferragutcasas, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Raquel Delgado Gil, Beatriz Villafranca Magdalena, Melek Denizli , Valeria Tubita
Funding agency: Asociación Española Contra el Cáncer
Funding: 188000
Reference: PERME212443COLA
Duration: 01/01/2022 - 31/01/2026

A dual liquid biopsy strategy in endometrial cancer: evaluation of risk of recurrence and pesonalized therapy.

IP: Antonio Gil Moreno
Collaborators: Vicente Bebia Conesa, Angel García Jiménez, Carina Masferrer Ferragutcasas, Ana Mazaltob Oaknin benzaquen, Montserrat Cubo Abert, Marta Rebull Santamaria, Mireia Armengol Alsina, Melek Denizli
Funding agency: Instituto de Salud Carlos III
Funding: 209330
Reference: PI20/01566
Duration: 01/01/2021 - 31/12/2023

ADVANCING ON THE DEVELOPMENT OF A NON-INVASIVE TOOL TO EARLY DIAGNOSE ENDOMETRIAL CANCER

IP: Eva Colas Ortega
Collaborators: Carina Masferrer Ferragutcasas, Fco Javier De la Torre Fdez de Vega, Silvia Cabrera Diaz, Anabel Montero Armengol, Irene De la Calle Fuentes, Beatriz Villafranca Magdalena
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI20/00644
Duration: 01/01/2021 - 31/12/2024

Targeting the most aggressive type of endometrial carcinoma

IP: Antonio Gil Moreno
Collaborators: Carina Masferrer Ferragutcasas, Marta Rebull Santamaria, Irene De la Calle Fuentes, Melissa Bradbury Lobato, Raquel Delgado Gil, Beatriz Villafranca Magdalena, Melek Denizli
Funding agency: Asociación Española Contra el Cáncer
Funding: 199250
Reference: GCTRA18014MATI
Duration: 18/02/2019 - 31/10/2024

Related news

The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies

The study evaluated the results of combining SYD985, a HER2 antibody conjugated to a potent cytotoxic drug, and niraparib, an inhibitor of DNA damage repair.

Researchers from the centre took part in international debates on AI in healthcare, spin-offs emerging from research were presented, and several initiatives linked to VHIR received recognition in the field of entrepreneurship.

Related professionals

Llorente Blasco, Helena

Llorente Blasco, Helena

Research technician
Clinical Neuroimmunology
Read more
Esteve Valverde, Enrique

Esteve Valverde, Enrique

Postdoctoral researcher
Systemic Diseases
Read more
de la Fuente Abelaira, Marisa

de la Fuente Abelaira, Marisa

Administration and Management
Research on Aging, Frailty and Transitions in Barcelona
Read more
Cedron Prieto, Sergio

Cedron Prieto, Sergio

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.